BioSpace News Archive

Koji Tanabe, Founder and CEO of I Peace, Inc. (https://www.ipeace.com ), has been selected by the judges of World Biz Magazine’s annual awards to be a recipient of the “Top 100 Innovation CEO – 2021” (https://www.worldbizmagazine.net/ ).

Kala Pharmaceuticals, Inc., announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635.

Life Sciences BC will be celebrating the BC life sciences sector and community at the 23rd Annual Life Sciences BC Awards, presented by FARRIS at 2pm PT on Thursday September 23, 2021.

VectivBio Holding AG, a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announced the closing of its previously announced acquisition of Comet Therapeutics, Inc., a privately held company that has been developing drugs to address previously untreatable Inherited Metabolic Diseases.

AIM ImmunoTech Inc. (NYSE American: AIM) today announced positive progress with the company’s meeting request to the U.S. Food and Drug Administration (FDA) concerning a Phase 2 clinical study of Ampligen

Stoke Therapeutics, Inc. announced positive safety, pharmacokinetic and cerebrospinal fluid exposure data from a planned interim analysis of the multi-center, open-label Phase 1/2a MONARCH study of STK-001 in children and adolescents with Dravet syndrome.

Statera Biopharma, Inc. will participate in the 2021 Cantor Virtual Global Healthcare Conference taking place September 27-30, 2001 .

Black Diamond Therapeutics and OpenEye Scientific announced that they are entering into a strategic partnership incorporating OpenEye’s Orion® molecular design platform into Black Diamond’s proprietary Mutation-Allostery-Pharmacology drug discovery engine to advance Black Diamond’s efforts to develop MasterKey inhibitor cancer therapies.

Small Pharma Inc. (TSXV: DMT) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies, today announced both the successful completion of the Phase I part of the combined Phase I/IIa clinical trial and the initiation of the Phase IIa part in combination with psychotherapy of its lead candidate, SPL026, for the treatment of Major Depressive Disorder (“MDD”).

Selecta Biosciences, Inc. today announced that Company’s Management will participate in a fireside chat and one-on-one investor meetings at the Cantor Virtual Global Healthcare Conference to be held September 27-30, 2021.